ARCH Venture Fund XIII, L.P. insider trades: Lyell Immunopharma (LYEL) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where ARCH Venture Fund XIII, L.P. reports to the SEC
Open-market buys and sales
4 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Nov 4, 2026 | LYEL | ↑ Buy | 2,321,262 | $10.77 | $25.0M | Indirect | Nov 5, 2026 (1d) |
| Jun 22, 2026 | KARD | ↑ Buy | 1,250,000 | $16.00 | $20.0M | By: ARCH Venture Fund XIII, L.P. | Jun 24, 2026 (2d) |
| Mar 6, 2026 | LYEL | ↑ Buy | 488,090 | $25.61 | $12.5M | Indirect | Mar 9, 2026 (3d) |
| Feb 3, 2025 | MTSR | ↑ Buy | 2,222,222 | $18.00 | $40.0M | Indirect | Feb 3, 2025 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other LYEL insiders
Open-market trades in the last 12 months
About ARCH Venture Fund XIII, L.P.'s insider trades
ARCH Venture Fund XIII, L.P. is a 10% owner of Lyell Immunopharma (LYEL). Since Feb 3, 2025, it has reported 4 open-market purchases worth $97.5M and no sales on SEC Form 4. In the last 12 months: 3 buys ($57.5M).
Its filings also include conversions (2 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every LYEL insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.